Skip to Content

Naltrexone Pregnancy and Breastfeeding Warnings

Naltrexone is also known as: Depade, Revia, Vivitrol

Medically reviewed on August 15, 2017.

Naltrexone Pregnancy Warnings

Naltrexone has been assigned to pregnancy category C by the FDA. Animal studies have revealed evidence of an embryocidal effect when given in doses approximately 30 to 60 times the human therapeutic dose. There are no adequate and controlled study data in human pregnancy. Naltrexone is only recommended for use during pregnancy when benefit outweighs risk.

See references

Naltrexone Breastfeeding Warnings

Naltrexone and 6-beta-naltrexol are excreted into human milk. The effects on the nursing infant are unknown. The manufacturer recommends that due to the potential for tumorigenicity shown for naltrexone in animal studies, and for the potential of serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

See references

References for pregnancy information

  1. "Product Information. ReVia (naltrexone)." DuPont Pharmaceuticals, Wilmington, DE.

References for breastfeeding information

  1. "Product Information. ReVia (naltrexone)." DuPont Pharmaceuticals, Wilmington, DE.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.